Bruno Matthew, Strober Bruce, Del Rosso James Q
Dermatology and Skin Cancer Surgery Center, Allen, Texas.
Clinical Professor of Dermatology, Yale University School of Medicine, New Haven, Connecticut, and Central Connecticut Dermatology, Cromwell, Connecticut.
J Clin Aesthet Dermatol. 2023 Sep;16(9 Suppl 1):S3-S12.
While corticosteroids and a limited number of nonsteroidal agents have formed the basis for United States Food and Drug Administration (FDA)-approved topical treatments of plaque psoriasis, there remains a need for efficacious nonsteroidal topical therapies in patients with psoriasis who cannot tolerate, do not respond well to, or wish to avoid topical corticosteroid therapy. Aryl hydrocarbon receptor (AhR) modulation has been shown to be an effective mechanism of action in the topical treatment of psoriasis. Currently there is only one FDA-approved, nonsteroidal, topical AhR modulating agent for the treatment of psoriasis. This educational activity seeks to broaden the treatment knowledge of the practicing dermatology community and inform them on the use of topical AhR modulating therapy as an addition to the advancing treatment armamentarium for patients with psoriasis.
虽然皮质类固醇和少数非甾体类药物构成了美国食品药品监督管理局（FDA）批准的斑块状银屑病局部治疗的基础，但对于那些无法耐受、对局部皮质类固醇治疗反应不佳或希望避免局部皮质类固醇治疗的银屑病患者，仍需要有效的非甾体类局部治疗方法。芳烃受体（AhR）调节已被证明是银屑病局部治疗的一种有效作用机制。目前，FDA仅批准了一种用于治疗银屑病的非甾体类局部AhR调节剂。本次教育活动旨在拓宽皮肤科执业人员的治疗知识，并告知他们局部AhR调节疗法可作为银屑病患者不断增加的治疗手段之一。
